MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SRRK stock logo

SRRK

Scholar Rock Holding Corporation

$45.58
1.78
 (4.06%)
Exchange:  NASDAQ
Market Cap:  5.462B
Shares Outstanding:  17.905M
Delayed data
Calculate SRRK Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  David L. Hallal
Full Time Employees:  128
Address: 
301 Binney Street
Cambridge
MA
2142
US
Website:  https://scholarrock.com
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/05/07 — Q1 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue000
Gross Profit-2,844-1,9370
EBITDA-162,945-237,520-369,388
Operating Income-171,295-252,054-384,645
Net Income-165,789-246,294-377,939

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets311,035474,922404,272
Total Liabilities85,817106,288158,784
Total Stockholders Equity225,218368,634245,488
Total Debt61,81865,126108,915
Cash and Cash Equivalents101,855177,878323,527

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-145,226-200,949-300,035
Capital Expenditure-71-98-602
Free Cash Flow-145,297-201,047-300,637
Net Income-165,789-246,294-377,939
Net Change in Cash-1,42076,023147,049

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)506,371.192Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)1,132,215.495Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)837,492.111Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)101,274.238Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)226,443.098Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)167,498.422Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)77,115.880Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)231,258.174Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)158,669.548Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)650,598.085Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)1,454,698.144Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)1,076,030.335Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.380Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)2.020Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)0.670Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)6Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)5Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
0  ?P/S
 (TTM)
: 
0
?Net Income
 (TTM)
: 
-246294000  ?P/E
 (TTM)
: 
-13.8
?Enterprise Value
 (TTM)
: 
5.084B  ?EV/FCF
 (TTM)
: 
-16.73
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.64  ?ROIC
 (TTM)
: 
-0.85
?Net Debt
 (TTM)
: 
-372152000  ?Debt/Equity
 (TTM)
: 
0.75
?P/B
 (TTM)
: 
20.43  ?Current Ratio
 (TTM)
: 
8.64

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
N/AFull AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about SRRK valuation

Is Scholar Rock Holding Corporation (SRRK) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Scholar Rock Holding Corporation (SRRK) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SRRK a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SRRK trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SRRK’s P/E ratio?

You can see SRRK’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SRRK?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SRRK a good long-term investment?

Whether SRRK fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

SRRK

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

4.06
MARKETSnap

Trading Metrics:

Open: 44.45   Previous Close: 43.8
Day Low: 43.73   Day High: 45.68
Year Low: 27.07   Year High: 52.19
Price Avg 50: 47.89   Price Avg 200: 41.65
Volume: 930431   Average Volume: 1.478M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
12-05-2026 14:20
Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Scholar Rock Q1 Earnings Call Highlights
08-05-2026 22:06
Scholar Rock Q1 Earnings Call Highlights
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
01-04-2026 13:40
SRRK Stock Jumps on Resubmission of FDA Filing for SMA Drug
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
03-03-2026 16:42
Scholar Rock Holding Corporation (SRRK) Q4 2025 Earnings Call Transcript
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
12-01-2026 13:15
Scholar Rock Holding Corporation (SRRK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read